C

Canberra Hospital | Gastroenterology Department

Research site
(Unclaimed)
Location
Canberra Hospital 8 Foursquare tips, Garran, Australian Capital Territory, Australia

Site insights

Top conditions

Top treatments

Bendamustine
Zanubrutinib
Carboplatin
Gemcitabine
LUM-201
Pembrolizumab
cyclophosphamide
Empagliflozin
prednisone
vincristine sulfate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

20 of 58 total trials

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficien...

Invitation-only
Growth Hormone Deficiency
Drug: LUM-201

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiov...

Enrolling
Obesity
Cardiovascular Diseases
Drug: Retatrutide
Drug: Placebo

The purpose of this study is to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response aft...

Enrolling
Lupus Nephritis
Drug: placebo
Drug: zetomipzomib

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic...

Active, not recruiting
Lung Diseases, Interstitial
Drug: BI 1015550
Drug: Placebo

This study is a prospective, multi-center, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Thera...

Active, not recruiting
Heart Failure
Device: WiSE System

Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed...

Active, not recruiting
Malignant Pleural Mesothelioma
Pleural Mesothelioma
Drug: Standard Chemotherapy
Drug: Durvalumab

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

Phase 3, randomized, multicentre study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficien...

Enrolling
Endometrial Cancer
Drug: Dostarlimab
Drug: Carboplatin-Paclitaxel

The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therap...

Active, not recruiting
Breast Cancer
Drug: Fulvestrant
Drug: Ipatasertib

The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead.The LEADR LBBAP study is being conducted under the exis...

Enrolling
Tachyarrhythmia
Device: Defibrillation (LBBAP Implant)
Device: Defibrillation (RV Implant)

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participant...

Active, not recruiting
Renal Cell Carcinoma (RCC)
Drug: Pazopanib
Drug: Epacadostat

This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) an...

Active, not recruiting
Growth Hormone Deficiency
Drug: rhGH Norditropin® pen (34 µg/kg)
Drug: LUM-201

This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's...

Enrolling
Primary Peritoneal Cancer
Fallopian Tube Cancer
Biological: Pembrolizumab
Biological: Nemvaleukin

The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The pha...

Enrolling
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Drug: Low-intensity chemotherapy regimen
Drug: Blinatumomab

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreat...

Active, not recruiting
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Drug: zanubrutinib
Drug: bendamustine

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Idelalisib
Drug: Bendamustine

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Overweight and Obesity
Drug: Retatrutide
Drug: Placebo

The purpose of this study is to evaluate the potential benefits of 145 mg of daily fenofibrate in adults with type 1 diabetes mellitus and pre-existi...

Enrolling
Diabetic Nephropathies
Type 1 Diabetes Mellitus
Drug: Inert lactose placebo
Drug: Fenofibrate

The TRACK trial is an investigator-initiated, multicentre, prospective, randomised, quadruple-blind (participant, healthcare provider, data collector...

Enrolling
Chronic Kidney Diseases
Dialysis-dependent Kidney Failure
Drug: Rivaroxaban 2.5 Mg Oral Tablet
Other: Placebo

Trial sponsors

Amgen logo
Boehringer Ingelheim logo
Lilly logo
Pfizer logo
C
BeiGene logo
Celgene logo
E
Gilead Sciences logo
L

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems